Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness

Journal of Applied Physiology

Volumn 102, Issue 4, 2007, Pages 1313-1322

  Leaf, David E ^a   Goldfarb, David S ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Nephrology Section/111G   (United States)

Author keywords

Altitude sickness; Carbonic anhydrase; Hypercapnic ventilatory response; Metabolic acidosis; Periodic breathing

Indexed keywords

ACETAZOLAMIDE;

ALTITUDE DISEASE; CHEMORECEPTOR; DIURESIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERVENTILATION; HYPOXIA; METABOLIC ACIDOSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY ACIDOSIS; RESPIRATORY ALKALOSIS; REVIEW;

ACETAZOLAMIDE; ADAPTATION, PHYSIOLOGICAL; ALTITUDE SICKNESS; CARBONIC ANHYDRASE INHIBITORS; HUMANS; OXYGEN; OXYGEN CONSUMPTION;

EID: 34147117348     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01572.2005     Document Type: Review

References (118)

1. Andreatta-van LS, Averill DB, Guertzenstein PG. Cardiorespiratory effects induced by acetazolamide on the ventromedullary surface of the cat. J Physiol 421: 171-184, 1990.
2. Anholm JD, Powles AC, Downey R III, Houston CS, Sutton JR, Bonnet MH, Cymerman A. Operation Everest II: arterial oxygen saturation and sleep at extreme simulated altitude. Am Rev Respir Dis 145: 817-826, 1992.
3. Aoki VS, Robinson SM. Body hydration and the incidence and severity of acute mountain sickness. J Appl Physiol 31: 363-367, 1971.
4. Arieff AI, Kerian A, Massry SG, DeLima J. Intracellular pH of brain: alterations in acute respiratory acidosis and alkalosis. Am J Physiol 230: 804-812, 1976.
5. Bailey DM, Roukens R, Knauth M, Kallenberg K, Christ S, Mohr A, Genius J, Storch-Hagenlocher B, Meisel F, McEneny J, Young IS, Steiner T, Hess K, Bartsch P. Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache. J Cereb Blood Flow Metab 26: 99-111, 2006.
6. Bartsch P, Jilg B, Hohenhaus E. Urine volume in acute mountain sickness is not related to hypoxic ventilatory response. Eur Respir J 8: 62S, 1995.
7. Bashir Y, Kann M, Stradling JR. The effect of acetazolamide on hypercapnic and eucapnic/poikilocapnic hypoxic ventilatory responses in normal subjects. Pulm Pharmacol 3: 151-154, 1990.
8. Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, Fleischman RJ, Gowder DW, Hawksworth JS, Jensen BT, Kleiman RJ, Loveridge AH, Lundeen EB, Newman SL, Noboa JA, Miegs DP, O'Beirne KA, Philpot KB, Schultz MN, Valente MC, Wiebers MR, Swenson ER. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 7: 17-27, 2006.
9. Berkenbosch A, Bovill JG, Dahan A, DeGoede J, Olievier IC. The ventilatory CO2 sensitivities from Read's rebreathing method and the steady-state method are not equal in man. J Physiol 411: 367-377, 1989.
10. Bickler PE, Litt L, Severinghaus JW. Effects of acetazolamide on cerebrocortical NADH and blood volume. J Appl Physiol 65: 428-433, 1988.
11. Birmingham Medical Research Expeditionary Society Mountain Sickness Study Group. Acetazolamide in control of acute mountain sickness. Lancet 1: 180-183, 1981.
12. Biscoe TJ, Purves MJ, Sampson SR. The frequency of nerve impulses in single carotid body chemoreceptor afferent fibres recorded in vivo with intact circulation. J Physiol 208: 121-131, 1970.
13. Brookfield DS, Liston WA, Brown GV. Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East Afr Med J 54: 689-691, 1977.
14. Brown GV, Liston WA, Brookfield DSK. Spironolactone in acute mountain sickness. Lancet 1: 855, 1977.
15. Cain SM, Dunn JE. Increase of arterial oxygen tension at altitude by carbonic anhydrase inhibition. J Appl Physiol 20: 882-884, 1965.
16. Cain SM, Dunn JE. Low doses of acetazolamide to aid accommodation of men to altitude. J Appl Physiol 21: 1195-1200, 1966.
17. 2 excretion and intravascular pH disequilibria during carbonic anhydrase inhibition. J Appl Physiol 84: 683-694, 1998.
18. Coates EL, Li AH, Nattie EE. Acetazolamide on the ventral medulla of the cat increases phrenic output and delays the ventilatory response to CO2. J Physiol 441: 433-451, 1991.
19. Collier DJ, Nathan J, Flower RJ, Wolff CB, Swenson ER, Milledge JS. Benzolamide, a selective carbonic anhydrase inhibitor, prevents acute mountain sickness: possible mechanisms. In: Hypoxia: Women at Altitude, edited by Houston CS and Coates G. Burlington, VT: Queen City Printers, 1997, p. 307.
20. Currie TT. Spironolactone and acute mountain sickness. Med J Aust 19: 419-420, 1977.
21. Currie TT, Carter PH, Champion WL, Fong G, Francis JK, McDonald IH, Newing RK, Nunn IN, Sisson RN, Sussex M, Zacharin RF. Spironolactone and acute mountain sickness. Med J Aust 2: 168-170, 1976.
22. Ehrenreich DL, Burns RA, Alman RW, Fazekas JF. Influence of acetazolamide on cerebral blood flow. Arch Neurol 5: 227-232, 1961.
23. Eichenberger U, Weiss E, Riemann D, Oelz O, Bartsch P. Nocturnal periodic breathing and the development of acute high altitude illness. Am J Respir Crit Care Med 154: 1748-1754, 1996.
24. Fischer R, Vollmar C, Thiere M, Born C, Leitl M, Pfluger T, Huber RM. No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia 24: 66-71, 2004.
25. 2 during prolonged acetazolamide treatment in humans. Am J Physiol Heart Circ Physiol 258: H954-H959, 1990.
26. Fujimoto K, Matsuzawa Y, Hirai K, Yagi H, Fukushima M, Shibamoto T, Koyama S, Levine BD, Kobayashi T. Irregular nocturnal breathing patterns high altitude in subjects susceptible to high-altitude pulmonary edema (HAPE): a preliminary study. Aviat Space Environ Med 60: 786-791, 1989.
27. Ghandour MS, Langley OK, Zhu XL, Waheed A, Sly WS. Carbonic anhydrase IV on brain capillary endothelial cells: a marker associated with the blood-brain barrier. Proc Natl Acad Sci USA 89: 6823-6827, 1992.
28. Goldenberg F, Richalet JP, Onnen I, Antezana AM. Sleep apneas and high altitude newcomers. Int J Sports Med 13, Suppl 1: S34-S36, 1992.
29. Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 116: 461-465, 1992.
30. Grossmann WM, Koeberle B. The dose-response relationship of acetazolamide on the cerebral blood flow in normal subjects. Cerebrovasc Dis 10: 65-69, 2000.
31. Hackett PH, Rennie D. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 2: 1149-1155, 1976.
32. Hackett PH, Rennie D. Acute mountain sickness. Semin Respir Med 5: 132-140, 1983.
33. Hackett PH, Rennie D, Hofmeister SE, Grover RF, Grover EB, Reeves JT. Fluid retention and relative hypoventilation in acute mountain sickness. Respiration 43: 321-329, 1982.
34. Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol 5: 136-146, 2004.
35. Hackett PH, Roach RC, Harrison GL, Schoene RB, Mills WJ Jr. Respiratory stimulants and sleep periodic breathing at high altitude. Almitrine versus acetazolamide. Am Rev Respir Dis 135: 896-898, 1987.
36. Hanson MA, Nye PC, Torrance RW. The location of carbonic anhydrase in relation to the blood-brain barrier at the medullary chemoreceptors of the cat. J Physiol 320: 113-125, 1981.
37. Hanson MA, Rao PS, Torrance RW. Carbon dioxide sensitivity of aortic chemoreceptors in the cat. Respir Physiol 36: 301-309, 1979.
38. - in respiratory acidosis. J Appl Physiol 40: 559-567, 1976.
39. Hayes MW, Maini BK, Torrance RW. Reduction of the responses of carotid chemoreceptors by acetazolamide. In: Morphology and Mechanisms of Arterial Chemoreceptors, edited by Paintal AS. Delhi, India: Vallabhbhai Patel Chest Institute University, 1976, p. 36-47.
40. Heinemann H, Goldring R. Bicarbonate and the regulation of ventilation. Am J Med 57: 370, 1974.
41. Honig A. Peripheral arterial chemoreceptors and reflex control of sodium and water homeostasis. Am J Physiol Regul Integr Comp Physiol 257: R1282-R1302, 1989.
42. Huang SY, McCullough RE, McCullough RG, Micco AJ, Manco-Johnson M, Weil JV, Reeves JT. Usual clinical dose of acetazolamide does not alter cerebral blood flow velocity. Respir Physiol 72: 315-326, 1988.
43. 2 responses in metabolic acidosis and alkalosis in humans. J Appl Physiol 48: 355-361, 1980.
44. -: role of carbonic anhydrase. J Appl Physiol 75: 1587-1594, 1993.
45. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L, Roselle GA. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 97: 2154-2159, 1998.
46. Javaheri S, Weyne J, Demeester G, Leusen I. Effects of acetazolamide on ionic composition of cisternal fluid during acute respiratory acidosis. J Appl Physiol 57: 85-91, 1984.
47. Jennum P, Jensen R. Sleep and headache. Sleep Med Rev 6: 471-479, 2002.
48. Joern AT, Shurley JT, Brooks RE, Guenter CA, Pierce CM. Shortterm changes in sleep patterns on arrival at the South Polar Plateau. Arch Intern Med 125: 649-654, 1970.
49. -]. J Appl Physiol 42: 667-672, 1977.
50. 3 in brain. Respir Physiol 28: 387-401, 1976.
51. Kiwull-Schone HF, Teppema LJ, Kiwull PJ. Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits. Am J Respir Crit Care Med 163: 478-483, 2001.
52. Klocke RA. Potential role of endothelial carbonic anhydrase in dehydration of plasma bicarbonate. Trans Am Clin Climatol Assoc 108: 44-58, 1996.
53. Kronenberg RS, Cain SM. Hastening respiratory acclimatization to altitude with benzolamide (CL 11,366). Aerospace Med 39: 296-300, 1968.
54. Kwatra SK, Viswanathan R. Effect of furosemide on altitude tolerance in experimental animals. Respiration 37: 109-113, 1979.
55. Lahiri S, Maret K, Sherpa MG. Dependence of high altitude sleep apnea on ventilatory sensitivity to hypoxia. Respir Physiol 52: 281-301, 1983.
56. Lahiri S, Mokashi A, Mulligan E, Nishino T. Comparison of aortic and carotid chemoreceptor responses to hypercapnia and hypoxia. J Appl Physiol 51: 55-61, 1981.
57. 2. Brain Res 234: 137-147, 1982.
58. Larson EB, Roach RC, Schoene RB, Hornbein TF. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 248: 328-332, 1982.
59. Lassen NA. Is central chemoreceptor sensitive to intracellular rather than extracellular pH? Clin Physiol 10: 311-319, 1990.
60. Lassen NA, Friberg L, Kastrup J, Rizzi D, Jensen JJ. Effects of acetazolamide on cerebral blood flow and brain tissue oxygenation. Postgrad Med J 63: 185-187, 1987.
61. Lee KD, Mattenheimer H. The biochemistry of the carotid body. Enzymol Biol Clin (Basel) 10: 199-216, 1964.
62. 2, Acetazolamid) auf die Lungenbelüftung Beim Menschen. Pflügers Arch 270: 450-460, 1960.
63. Linton RA, Poole-Wilson PA, Davies RJ, Cameron IR. A comparison of the ventilatory response to carbon dioxide by steady-state and rebreathing methods during metabolic acidosis and alkalosis. Clin Sci Mol Med Suppl 42: 239-249, 1973.
64. Loeppky JA, Icenogle MV, Maes D, Riboni K, Hinghofer-Szalkay H, Roach RC. Early fluid retention and severe acute mountain sickness. J Appl Physiol 98: 591-597, 2005.
65. 2-Druckes. Pflügers Arch Ges Physiol 267: 477, 1958.
66. Maren TH. Carbonic anhydrase: chemistry, physiology, inhibition. Physiol Rev 47: 595-781, 1967.
67. - formation in cerebrospinal fluid. J Appl Physiol 47: 471-477, 1979.
68. 2. Jpn J Physiol 39: 523-535, 1989.
69. McCloskey DI. Carbon dioxide and the carotid body. In: Arterial Chemoreceptors, edited by Torrance RW. Oxford: Blackwell, 1968, p. 101-133.
70. Messeter K. The effect of acetazolamide upon the regulation of the cerebrospinal fluid pH in the rat. Acta Physiol Scand 85: 58-70, 1972.
71. Mitchell RA, Loeschcke HH, Massion WH, Severinghaus JW. Respiratory responses mediated through superficial chemosensitive areas on the medulla. J Appl Physiol 18: 523-533, 1963.
72. Nattie EE. Ventilation during acute HCl infusion in intact and chemodenervated conscious rabbits. Respir Physiol 54: 97-107, 1983.
73. 2 saturation in relation to sleep stages at high altitude. Aviat Space Environ Med 61: 229-235, 1990.
74. Oh MS, Carroll HJ. Mechanism of chloride deficit in the maintenance of metabolic alkalosis. Nephron 91: 379-382, 2002.
75. Phillipson EA. Control of breathing during sleep. Am Rev Respir Dis 118: 909-939, 1978.
76. Reite M, Jackson D, Cahoon RL, Weil JV. Sleep physiology at high altitude. Electroencephalogr Clin Neurophysiol 38: 463-471, 1975.
77. Ridderstrale Y, Hanson MA. Histochemical localization of carbonic anhydrase in the cat carotid body. Ann NY Acad Sci 429: 398-400, 1984.
78. Ried LD, Carter KA, Ellsworth A. Acetazolamide or dexamethasone for prevention of acute mountain sickness: a meta-analysis. J Wilderness Med 5: 34-48, 1994.
79. Rigual R, Iniguez C, Carreres J, Gonzalez C. Carbonic anhydrase in the carotid body and the carotid sinus nerve. Histochemistry 82: 577-580, 1985.
80. 2 stimulation of the cat carotid body. J Physiol 433: 519-531, 1991.
81. Roach RC, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 204: 3161-3170, 2001.
82. Roth LJ, Schoolar JC, Barlow CF. Sulfur-35 labeled acetazolamide in cat brain. J Pharmacol Exp Ther 125: 128-136, 1959.
83. Salvaggio A, Insalaco G, Marrone O, Romano S, Braghiroli A, Lanfranchi P, Patruno V, Donner CF, Bonsignore G. Effects of high-altitude periodic breathing on sleep and arterial oxyhaemoglobin saturation. Eur Respir J 12: 408-413, 1998.
84. Severinghaus JW, Bainton CR, Carcelen A. Respiratory insensitivity to hypoxia in chronically hypoxic man. Respir Physiol 1: 308-334, 1966.
85. Singh I, Khanna PK, Srivastava MC, Lal M, Roy SB, Subramanyam CS. Acute mountain sickness. N Engl J Med 280: 175-184, 1969.
86. Skatrud JB, Dempsey JA. Relative effectiveness of acetazolamide versus medroxyprogesterone acetate in correction of chronic carbon dioxide retention. Am Rev Respir Dis 127: 405-412, 1983.
87. Smith CA, Nakayama H, Dempsey JA. The essential role of carotid body chemoreceptors in sleep apnea. Can J Physiol Pharmacol 81: 774-779, 2003.
88. Sundstrom ES. Studies on adaptation of man to high altitudes. V. Effect of high altitudes on salt metabolism. Univ Calif Publ Physiol 5: 121-132, 2006.
89. Sutton J. Acute mountain sickness. An historical review, with some experiences from the Peruvian Andes. Med J Aust 2: 243-248, 1971.
90. Sutton JR, Houston CS, Mansell AL, McFadden MD, Hackett PM, Rigg JR, Powles AC. Effect of acetazolamide on hypoxemia during sleep at high altitude. N Engl J Med 301: 1329-1331, 1979.
91. Swenson ER. Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and suppression. Eur Respir J 12: 1242-1247, 1998.
92. Swenson ER. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 151: 209-216, 2006.
93. Swenson ER. High-altitude diuresis: fact or fancy. In: Hypoxia: Women at Altitude, edited by Houston CS and Coates G. Burlington VT: Queen City Printers, 2006, p. 272-283.
94. Swenson ER, Duncan TB, Goldberg SV, Ramirez G, Ahmad S, Schoene RB. Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones. J Appl Physiol 78: 377-383, 1995.
95. Swenson ER, Hughes JM. Effects of acute and chronic acetazolamide on resting ventilation and ventilatory responses in men. J Appl Physiol 74: 230-237, 1993.
96. Swenson ER, Leatham KL, Roach RC, Schoene RB, Mills WJ Jr, Hackett PH. Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing. Respir Physiol 86: 333-343, 1991.
97. 2 transport at rest and during maximal exercise. Respir Physiol 35: 129-159, 1978.
98. Teppema LJ, Bijl H, Gourabi BM, Dahan A. The carbonic anhydrase inhibitors methazolamide and acetazolamide have different effects on the hypoxic ventilatory response in the anaesthetized cat. J Physiol 574: 565-572, 2006.
99. 2 sensitivity? Am J Respir Crit Care Med 160: 1592-1597, 1999.
100. Teppema LJ, Rochette F, Demedts M. Ventilatory response to carbonic anhydrase inhibition in cats: effects of acetazolamide in intact vs. peripherally chemodenervated animals. Respir Physiol 74: 373-382, 1988.
101. 2 and hypoxia in humans. Jpn J Physiol 36: 511-521, 1986.
102. Torrance RW. Arterial chemoreceptors. In: Respiratory Physiology, edited by Widdicombe JG. Baltimore, MD: University Park Press, 1974, p. 247-271.
103. Torrance RW. Convergence of stimuli in arterial chemoreceptors. Adv Exp Med Biol 78: 203-207, 1977.
104. 2 is inert on carotid chemoreceptor: demonstration by inhibition of carbonic anhydrase. J Pharmacol Exp Ther 178: 529-540, 1971.
105. 2 transport in blood at hypoxic hypoxia. Adv Exp Med Biol 180: 357-368, 1984.
106. Vardy J, Vardy J, Judge K. Acute mountain sickness and ascent rates in trekkers above 2500 m in the Nepali Himalaya. Aviat Space Environ Med 77: 742-744, 2006.
107. Vogh BP, Maren TH. Sodium, chloride, and bicarbonate movement from plasma to cerebrospinal fluid in cats. Am J Physiol 228: 673-683, 1975.
108. Vorstrup S, Henriksen L, Paulson OB. Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen. J Clin Invest 74: 1634-1639, 1984.
109. Vos PJ, Folgering HT, de Boo TM, Lemmens WJ, van Herwaarden CL. Effects of chlormadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 7: 850-855, 1994.
110. Vovk A, Duffin J, Kowalchuk JM, Paterson DH, Cunningham DA. Changes in chemoreflex characteristics following acute carbonic anhydrase inhibition in humans at rest. Exp Physiol 85: 847-856, 2000.
111. 2 response curve in the anaesthetized cat. J Physiol 495: 227-237, 1996.
112. Weil JV, Kryger MH, Scoggin CH. Sleep and breathing at high altitude. In: Sleep Apnea Syndromes. New York: Liss, 1978, p. 119-123.
113. Weil JV. Sleep at high altitude. In: Principles and Practice of Sleep Medicine, edited by Kryger MH, Roth T, and Dement WC. Philadelphia, PA: Saunders, 1989, p. 269-275.
114. Weil JV. Sleep at high altitude. High Alt Med Biol 5: 180-189, 2004.
115. West JB. High Life: A History of High-Altitude Physiology and Medicine. New York: Oxford University Press, 1998.
116. West JB. The physiologic basis of high-altitude diseases. Ann Intern Med 141: 789-800, 2004.
117. Wickramasinghe H, Anholm JD. Sleep and breathing at high altitude. Sleep Breath 3: 89-102, 1999.
118. Zielinski J, Koziej M, Mankowski M, Sarybaev AS, Tursalieva JS, Sabirov IS, Karamuratov AS, Mirrakhimov MM. The quality of sleep and periodic breathing in healthy subjects at an altitude of 3,200 m. High Alt Med Biol 1: 331-336, 2000.